ClinicalTrials.gg
RecruitingNCT07135284Updated Apr 13, 2026

Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)

An observational study in Bronchiectasis Adult, sponsored by Synchrony-Medical, Ltd. Recruiting at 3 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Synchrony-Medical, Ltd · Observational

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Planned enrollment
6th of 13
200 · median 100
Started
2025
with 4 others
Observational
13 of 65
6 open now
Primary completion
2027-02
later than 7 of 21 live
Registered
56th of 65
by date

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 6th largest by planned enrollment of the 13 observational ones that give a count, is one of 5 that started in 2025, is one of 13 observational ones, reaches primary completion later than 7 of the 21 other live ones, and was the 56th registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to collect data to assess the use of the LibAirty™ System for improving bronchiectasis symptoms and healthcare resource utilization when it is used at home.

The main question this study is trying to answer is: How often do adults with bronchiectasis experience pulmonary exacerbations (flare-ups of their lung condition) while using the LibAirty™ airway clearance system at home?

Participants will use the LibAirty™ airway clearance system at home as prescribed by their doctor - the device is not being provided as part of the study. The study will last for 12 months from the time participants begin using LibAirty.

During the study period, participants will continue with their usual clinic visits. At some of these regular visits (up to 4 times over the year), participants will be asked to complete short questionnaires about their bronchiectasis symptoms and their experience using LibAirty. At these same visits, the study team will also review participants' medical records and collect information related to their bronchiectasis condition, such as test results, medications, and any hospital or emergency room visits.

Read the detailed description

This prospective, single-arm, open-label study aims to evaluate the real-world use of the LibAirty™ Airway Clearance System for airway clearance in adult patients with bronchiectasis in a home setting. The primary objective is to assess the rate of pulmonary exacerbations during the 12-month study period, compared to the 12 months prior to enrollment, using each participant as their own historical control.

Importantly, this study is observational in nature. Participants are prescribed the LibAirty™ system by their treating physician as part of routine clinical care, independent of study enrollment. The study does not assign participants to receive the device, nor does it provide the device as part of the study. Participants will use the LibAirty™ system in the same manner and frequency as they would outside of the study, based on the physician's clinical judgment and standard treatment protocols.

The study will observe clinical outcomes in participants who are already prescribed the device. Data will be collected prospectively during regularly scheduled clinic visits that occur as part of each participant's standard care. At up to four of these visits, information will be gathered from medical records, and participants will complete validated questionnaires to assess health-related quality of life and user satisfaction with the LibAirty™ system. Adherence to therapy will be assessed using usage logs recorded by the device.

Additional clinical outcomes such as hospitalizations, emergency department visits, use of antibiotics for exacerbations, pulmonary function test results, and healthcare resource utilization related to bronchiectasis will be monitored. No investigational procedures, treatments, or interventions are introduced or modified by the study team.

This study is designed to generate real-world evidence on the effectiveness, adherence, and patient experience associated with the LibAirty™ system when used as part of standard bronchiectasis care in the home setting.

03

Conditions studied

  • Bronchiectasis Adult

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with bronchiectasis who have been prescribed the LibAirty airway clearance system as part of their standard care. Participants will be identified and recruited from outpatient pulmonary or respiratory clinics affiliated with participating study sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a radiological diagnosis of Bronchiectasis based on high resolution chest CT scan
  2. Have bronchiectasis characterized by either:

    • Daily productive cough (as determined by a treating physician)
    • OR Available documentation from the last 12 months of 2 or more pulmonary exacerbations requiring antibiotic therapy
  3. Be at age ≥ 21 years
  4. Prescribed and receives the LibAirty system for home use
  5. Be on a standard of care treatment plan that includes at least one physician encounter every 6 months
  6. No change in treatment for Bronchiectasis in the 2-month period prior to enrollment
  7. Signed

Exclusion criteria

Exclusion Criteria:

  1. Inability to independently perform therapy with the LibAirty system as directed
  2. Any other condition that, in the opinion of the PI, could jeopardize the safety of the subject or impact the validity of the study results.
  3. Pregnancy or planned pregnancy during the expected duration of the trial (12 months).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults with bronchiectasis

    Adults with bronchiectasis, prescribed with the LibAirty airway clearance system

    Device: Airway clearance system

Interventions

  • DeviceAirway clearance system

    The device is prescribed as part of each participant's regular medical care, independently of the study. The study does not assign the device or alter standard treatment. Participants are observed while using the device as part of their usual care.

06

What researchers measure

Primary outcomes

  1. The primary endpoint for this study is the rate of pulmonary exacerbations (PE).

    Time frame: 12 months

Secondary outcomes

  1. Rate of respiratory related hospitalizations, including length of stay

    Time frame: 12 months

  2. Rate of severe PEs (requiring IV antibiotics and/or hospitalization)

    Time frame: 12 months

  3. Number of respiratory related ED visits

    Time frame: 12 months

  4. Change from Baseline in PFTs (FEV1)

    Time frame: 12 months

  5. Change from Baseline in PFTs (FVC)

    Time frame: 12 months

  6. Change from Baseline in PFTs (FEV1/FVC)

    Time frame: 12 months

  7. Change from baseline in Quality of Life (QoL-B)

    Time frame: 12 months

  8. User satisfaction with the LibAirty system

    Evaluated using a LibAirty™ system user satisfaction questionnaire

    Time frame: 12 months

  9. Adherence to therapy

    Adherence to therapy will be evaluated using device usage logs

    Time frame: 12 months

  10. Healthcare resource utilization resulting from respiratory condition

    Cost of treatments, hospitalizations and ED visits

    Time frame: 12 months

Other outcomes

  1. Time to first PE and median time between PEs

    Time frame: 12 months

  2. Percent of patients who have not experienced a PE for 6 months and 12 months

    Time frame: 6 months and 12 months

  3. Number of courses of antibiotics prescribed for pulmonary exacerbations, including duration and route of administration

    Time frame: 12 months

07

Study locations

3 of 3 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.

Of 61 observational studies under Bronchiectasis, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 12. This study's planned 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Aug 22, 2025
StartActual
Aug 20, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07135284
Lead sponsor
Synchrony-Medical, Ltd
Responsible party
Sponsor
First posted
Aug 22, 2025
Start date
Aug 20, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion